1. Introduction
===============

Severe sepsis is a common intensive care unit (ICU) admission diagnosis and consumes vast amounts of precious healthcare resources.^\[[@R1]\]^ Despite improvements in resuscitation techniques, antibiotic therapy, and source control measures, mortality rates associated with severe sepsis rates still remains unacceptably high.^\[[@R2]\]^

Severe sepsis is characterized by a marked systemic inflammatory response syndrome (SIRS) to infection.^\[[@R3]\]^ Animal studies and observational human studies have indicated that statins have anti-inflammatory, antioxidant, and immune-modulating effects,^\[[@R4]\]^ which may attenuate the inflammatory response to sepsis.^\[[@R5]\]^ Since 2009, several small published randomized controlled trials have explored the potential beneficial effects of statins on mortality rates in patients with sepsis, with controversial results. In addition, some previous systematic reviews and meta-analysis have summarized the findings of relevant studies on the association between statin use and outcome of septic patients.^\[[@R6]--[@R9]\]^ However, these studies used different inclusion criteria and sample size, and thus the results were also controversial.

Recently, several new randomized control trials on this topic have been reported. Therefore, we performed the present updated systematic review and meta-analysis of all available placebo-controlled randomized trials with the primary objective of summarizing evidence about the effect of statin therapy on mortality from sepsis.

2. Methods
==========

2.1. Search strategies
----------------------

This study was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.^\[[@R10]\]^ A comprehensive searching was performed in the following electronic databases: PubMed, Embase, and Cochrane controlled trials register. The dates searched were from the inception of each database to December 2017. The following keywords and their combinations were used as search strategy: ("statin" or "hydroxymethylglutarylcoenzyme A reductase inhibitors" or "anticholesteremic agents" or "simvastatin" or "rosuvastatin" or "pravastatin" or "atorvastatin" or "fluvastatin" or "cerivastatin" or "pitavastatin" or "lovastatin") and ("infection" or "sepsis" or "bacteremia" or "pneumonia") and ("randomized" or "randomization" or "random" or "randomness"). The bibliographies of relevant articles and reviews were also checked for additional studies. There were no limitations for language or publication date. This is a systematic review and meta-analysis, which was based on previous published studies and did not have original data. Therefore, no ethical approval and patient consent are required.

2.2. Inclusion and exclusion criteria
-------------------------------------

Included studies met all the following criteria: randomized trial; evaluated the effect of statin therapy on mortality in patients with sepsis; drop-out rate was \<20%; provided enough data to calculate relative risk (RR) and its 95% confidence interval (CI). Letters to the editor and conference abstracts were excluded from this study because of insufficient description of study methodology. Study selection was independently performed by 2 authors (MC and MJ), with divergences resolved by consensus.

2.3. Data extraction
--------------------

Data extraction from each included article was performed by the same 2 independent authors (MC and MJ) with a predesigned data collection form. The following information was recorded: study design, study population/setting, primary outcome, duration of follow-up, type of statin and dose. The primary outcome of this study was 28-day mortality. The second outcome was in-hospital mortality.

2.4. Evaluation of study quality
--------------------------------

The quality evaluation was performed with a 5-item instrument proposed by Jadad et al.^\[[@R11]\]^ Each item represents one point. A study with ≤ 2 points was considered low quality and \> 2 points was considered high quality. The quality assessment was completed by 2 independent authors (MC and MJ). Any disagreements were resolved by consensus.

2.5. Statistical analysis
-------------------------

The combined RR with its 95% CI was calculated with a Mantel--Haenszel fixed-effects model with a value of \< 1 favoring statins.^\[[@R12]\]^ Heterogeneity across included trials was evaluated using the Cochran chi-square test and the *I*^*2*^ statistic.^\[[@R13]\]^ Publication bias was assessed with a visual plot. Statistical analyses were performed using STATA 10.0 (StataCorp, College Station, TX) with two-sided *P* values (set at .05).

3. Results
==========

3.1. Study selection
--------------------

The detailed process of study searching is outlined in Figure [1](#F1){ref-type="fig"}. We identified 285 potentially eligible studies. Most of them were excluded after reading titles and/or abstracts. 46 studies were further evaluated by full-text reading. Ultimately, 9 of the 46 studies were included in our study; of those not included, 35 were excluded because the study design was observational study, 2 because ward patients were included, and one because it included patients without sepsis.

![Flow of study selection.](medi-97-e11578-g001){#F1}

3.2. Study characteristics and quality
--------------------------------------

All the included studies were published as peer-reviewed articles and all of them were in English.

A total of 2333 sepsis patients were recruited to these 9 trials;^\[[@R14]--[@R22]\]^ 1163 were randomized to the statin group and 1170 to the control group. All trials were placebo controlled. All included studies defined sepsis according to the American College of Chest Physicians/Society of Critical Care of Medicine Consensus Conference definitions (Sepsis Definition-1).^\[[@R23]\]^ All the trials recruited sepsis patients without recent statin usage. Of the 9 trials, patients in 4 trials received atorvastatin,^\[[@R14],[@R15],[@R19],[@R22]\]^ patients in 3 trials received simvastatin,^\[[@R16]--[@R18]\]^ and patients in 2 trials received rosuvastatin.^\[[@R20],[@R21]\]^ Four trials reported in-hospital mortality,^\[[@R14],[@R17],[@R20],[@R21]\]^ 2 trials reported 28-day mortality,^\[[@R19],[@R22]\]^ and 3 trials reported both as outcome of interest.^\[[@R15],[@R16],[@R18]\]^ Detailed characteristics of the included studies are presented in Table [1](#T1){ref-type="table"}.

###### 

Basic characteristics of included randomized controlled trials.

![](medi-97-e11578-g002)

The quality of the included studies was assessed by Jadad scores, and the median Jadad score of the included studies was 5 (range, 4--5). Methods of randomization and allocation concealment were adequately addressed in the majority of trials. All 9 included studies were double-blind. All trials clearly stated withdrawals and dropouts (Table [2](#T2){ref-type="table"}).

###### 

Jadad scoring of randomized controlled trials.
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3.3. Data synthesis
-------------------

### 3.3.1. In-hospital mortality

Seven randomized trials were eligible for the in-hospital mortality analysis. There were 257 deaths among 1078 individuals in the statin treatment group and 268 deaths among 1081 individuals in the control group. There was no statistically significant difference (RR, 0.96; 95% CI, 0.83--1.11) (Fig. [2](#F2){ref-type="fig"}). There was no significant heterogeneity of findings across the studies (*I*^2^ = 20%, *P = *.28).

![Summary effects of statins versus placebo on changes in in-hospital mortality.](medi-97-e11578-g004){#F2}

### 3.3.2. 28-day hospital mortality

Five randomized trials reported data on 28 day-hospital mortality. There were 123 deaths among 613 individuals in the statin treatment group and 141 deaths among 633 individuals in the control group. There was no statistically significant difference (RR, 0.90; 95% CI, 0.73--1.11) (Fig. [3](#F3){ref-type="fig"}). No significant heterogeneity was observed among the studies (*I*^2^ = 29%, *P* = .23).

![Summary effects of statins versus placebo on changes in 28-day mortality.](medi-97-e11578-g005){#F3}

3.4. Publication bias
---------------------

Visual inspection of funnel plot did not identify a skewed or asymmetrical shape, excluding the presence of small publication bias (Fig. [4](#F4){ref-type="fig"}).

![Funnel plot for the risk of (A) in-hospital mortality and (B) 28-day mortality.](medi-97-e11578-g006){#F4}

4. Discussion
=============

The present meta-analysis summarizes the results of 9 randomized trials, including 2333 sepsis patients. To the best of our knowledge, this is the largest meta-analysis of clinical trials evaluating the effect of statin therapy on mortality in patients with sepsis. The results indicated that statin use did not improve mortality outcomes in septic patients compared with placebo.

Recently, the potential relationship between statin therapy and mortality in patients with sepsis has captured attention and published results on this association have been contradictory. A meta-analysis performed by Janda et al^\[[@R24]\]^ included 20 studies (only 1 randomized control trial) and suggested a protective effect for statins in patients with sepsis. Another meta-analysis of observational studies by Tleyjeh et al^\[[@R25]\]^ also indicated that statin use might be associated with a beneficial effect in treating and preventing various infections. A study by Wan et al^\[[@R9]\]^ summarized the evidence from 5 clinical trials and 27 observational studies. They found a survival advantage in meta-analysis of observational studies but not in randomized controlled trials. Rothenberg et al^\[[@R7]\]^ systematically reviewed of statin in critically ill patients and concluded that aspirin might play a role in reducing mortality in non-cardiac critically ill patients. Quinn et al^\[[@R6]\]^ found that statins use did not significantly improve either in-hospital mortality or 28-day mortality in patients with sepsis with a systematic review and meta-analysis. Deshpande et al^\[[@R26]\]^ and Pasin et al^\[[@R8]\]^ also performed a meta-analysis of 7 trials and 5 trials, respectively. They concluded that treatment with statin could not improve a septic patient\'s outcome. Up to now, several new randomized control trials on this topic have been performed. Our meta-analysis included the more recent studies and thereby had larger sample size; potentially improved statistical power. In addition, our study only included high quality randomized control trials, which reduced the heterogeneity across studies (no obvious heterogeneity was observed in this study) and enhanced the robustness of our findings.

The main findings from the present meta-analysis of clinical trials were inconsistent with those of observational studies, which may be due to the methodological differences between clinical trials and observational studies. Observational studies can't completely avoid unknown or unquantified confounders, which are inherent to the study design. In particular, "healthy user" effect is one major source of such potentially confounding factors.^\[[@R27]\]^ Another limitation of meta-analysis based on observational studies was the significant heterogeneity across studies. By contrast, our meta-analysis of clinical trials is able to control the "healthy-user" effect. In addition, no obvious heterogeneity is detected in our study.

There are several important limitations should be considered in interpreting the results of our meta-analysis. First, although visual inspection of funnel plot did not identify a skewed or asymmetrical shape, some inevitable publication bias may exist. Second, the overall sample size of the contributing studies in specific outcome analysis was still small. Third, despite generally similar demographic characteristics and no significant evidence of heterogeneity across these clinical trials, some confounding factors such as difference in statin type and dose, early definition, and early antimicrobial therapy might affect the results of statin therapy and thus cause potential bias. A meta-analysis is unable to solve problems with confounders that could be inherent in the original studies.^\[[@R28]\]^ Finally, because most included studies did not provide risk estimates according to different dose, we were not able to evaluate the effect of different dose on mortality outcomes in septic patients.

Our study also had some important strength. To date, little is known about the effects of statin therapy on mortality in patients with sepsis, although observational studies have suggested a protective effect. Several randomized trials have been performed to evaluate the relationship between statin use and the mortality outcome in septic patients, but the results were inconsistent and conflicting. As individual studies may have insufficient statistical power, the current systematic review and meta-analysis of 9 randomized trials involving relatively large samples of sepsis patients enhanced the statistical power to detect an important difference and provided more reliable estimates.

5. Conclusion
=============

The present meta-analysis based on 9 prospective randomized trials indicated that statin therapy could not improve mortality in septic patients compared with placebo-controls.
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